Clinical Trials

41 enrolled

Pancreatic Neoplasms

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

200 enrolled

Nasopharyngeal Carcinoma

NCT03046862 2024-04-19

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

31 enrolled

Biliary Tract Neoplasms

NCT03572400 2024-04-19

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

71 enrolled

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

77 enrolled

Pancreatic Neoplasms

NCT06030622 2024-04-19

C3

25 enrolled

Pancreatic Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled

Pancreatic Neoplasms

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT05064618 2024-04-04

MIKE-1

55 enrolled

Pancreatic Neoplasms

NCT03721744 2024-04-03

A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

Phase 2/3 Unknown

336 enrolled

Pancreatic Neoplasms

NCT04674956 2024-04-02

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

401 enrolled

Pancreatic Neoplasms

NCT05048524 2024-03-27

Peri-operative SLOG for Localized Pancreatic Cancer

64 enrolled

Pancreatic Neoplasms

NCT05671900 2024-03-08

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

70 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT04934514 2024-02-20

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

97 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05626101 2024-02-13

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

280 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05189028 2024-02-06

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

290 enrolled

Uterine Cervical Neoplasms

NCT06211881 2024-01-18

Chi-GVM Regimen for the Treatment of R/R PTCL

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Unknown

75 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

460 enrolled

Nasopharyngeal Carcinoma

NCT05580445 2023-11-22

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

114 enrolled

Advanced Pancreatic Cancer

NCT04338763 2023-11-18

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Phase 1 Unknown

48 enrolled

Pancreatic Neoplasms

NCT00657878 2023-11-13

MITO-8

215 enrolled

Ovarian Neoplasms

NCT06055348 2023-09-26

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

112 enrolled

Serous Ovarian Cancer

NCT06041035 2023-09-18

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

115 enrolled

Other solid neoplasm

Solid Tumor

NCT04324307 2023-09-01

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

123 enrolled

Breast

Breast Cancer Metastatic

NCT05979298 2023-08-07

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

40 enrolled

Ovarian Neoplasms

NCT04522050 2023-07-12

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 1 Unknown

65 enrolled

Nasopharyngeal Carcinoma

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

34 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

NCT05795920 2023-04-03

Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT03700476 2023-03-28

CONTINUUM

425 enrolled

Nasopharyngeal Neoplasms

NCT01405586 2023-03-24

MILES-3

299 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01656551 2023-03-24

MILES-4

232 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05723991 2023-02-13

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Phase 4 Unknown

36 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05701332 2023-01-27

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Phase 4 Unknown

25 enrolled

Fibrosis, Oligospermia

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

70 enrolled

Cholangiocarcinoma

NCT05647330 2022-12-12

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

55 enrolled

Lung Neoplasms

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

40 enrolled

Resectable Biliary Tract Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled